AbbVie Raises 2027 Combined Sales Outlook for Skyrizi and Rinvoq To Over $27B; Raises Peak Sales Outlook for Ubrelvy and Qulipta To Over $3B Combined
Portfolio Pulse from Benzinga Newsdesk
AbbVie has updated its sales outlook, projecting combined sales for Skyrizi and Rinvoq to exceed $27 billion by 2027. Additionally, the company has raised its peak sales forecast for Ubrelvy and Qulipta, expecting them to collectively surpass $3 billion.
February 02, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has significantly raised its sales outlook for key products Skyrizi and Rinvoq to over $27 billion by 2027 and for Ubrelvy and Qulipta to over $3 billion combined.
AbbVie's upward revision of sales forecasts for Skyrizi, Rinvoq, Ubrelvy, and Qulipta directly impacts its revenue potential and growth outlook. This positive news is likely to boost investor confidence and could lead to a short-term increase in ABBV's stock price, given the significant contribution these products are expected to make to the company's overall sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100